Compagnie Lombard Odier SCmA’s CRISPR Therapeutics CRSP Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-600	Closed	-$43.5K	–	643
2022 Q2	$36K	Hold	600	–	–	﹤0.01%	477
2022 Q1	$38K	Sell	600 -1,100	-65%	-$69.1K	﹤0.01%	478
2021 Q4	$128K	Sell	1,700 -700	-29%	-$61.2K	﹤0.01%	411
2021 Q3	$268K	Buy	2,400 +100	+4%	+$12.6K	0.01%	316
2021 Q2	$372K	Buy	2,300 +1,525	+197%	+$185K	0.01%	269
2021 Q1	$95K	Buy	775 +375	+94%	+$56.6K	﹤0.01%	451
2020 Q4	$61K	Buy	+400	New	+$47.3K	﹤0.01%	415
2018 Q4	–	Sell	-800	Closed	-$35K	–	563
2018 Q3	$35K	Hold	800	–	–	﹤0.01%	454
2018 Q2	$47K	Buy	+800	New	+$45.6K	﹤0.01%	441

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Compagnie Lombard Odier SCmA's CRSP Position: Q3 2022 in Review

Compagnie Lombard Odier SCmA sold out of CRISPR Therapeutics (CRSP) in Q3 2022, closing a stake of 600 shares — an estimated $43.5K sold.

Compagnie Lombard Odier SCmA first reported a position in CRSP in Q2 2018 and held it in 9 quarters. The position peaked at $372K in Q2 2021. 436 funds tracked by Wall St. Rank hold CRSP as of Q3 2022.

Compagnie Lombard Odier SCmA reported no remaining CRISPR Therapeutics position as of Q3 2022 after selling out during the quarter.
Compagnie Lombard Odier SCmA sold 600 CRISPR Therapeutics shares in Q3 2022, an estimated $43.5K.
Compagnie Lombard Odier SCmA first reported a position in CRISPR Therapeutics in Q2 2018 and held it in 9 quarters.
Compagnie Lombard Odier SCmA's CRISPR Therapeutics position peaked at $372K in Q2 2021.
436 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2022.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q3 2022, filed 9 Nov 2022.